Plain-English translation of NCT06826430 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage (Phase I) clinical trial testing a new cell therapy called for people with a serious blood condition called immune thrombocytopenia that occurs alongside lupus. The medication is a type of living cell treatment where your own immune cells are collected, modified in a laboratory to help fight the problem, and then infused back into your body. Researchers are studying whether this treatment is safe and well-tolerated, and what dose works best.
People with lupus-related immune thrombocytopenia often do not respond well to standard treatments like steroids and immunosuppressive medications, leaving them at risk for serious bleeding. This medication represents a new approach using modified cells to potentially restore normal platelet counts in people whose condition has proven difficult to treat.
You likely qualify if…
You likely don't qualify if…
You will first go through a screening phase to confirm you qualify. If accepted, you will receive chemotherapy to prepare your body, then have the modified cell treatment infused intravenously. You will then be followed closely for 2 years with regular visits and blood tests to monitor your platelet counts, symptoms, and any side effects. The study involves careful tracking of your safety and how well the treatment works over this period.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Juventas Cell Therapy Ltd.
Enrollment target
~12 participants
Started
March 2025
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Junyin Yu
Peking Union Medical College
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.